Today, type 2 diabetes has become a worldwide epidemic, with 114 million people living with the disease in China, 90% of whom have type 2 diabetes, most of whom are overweight and obese to varying degrees. As early as 1982, Prries, a surgeon at the University of North Carolina, discovered by chance that bariatric surgery could treat obese type 2 diabetes, and in 1995 reported the results of a 14-year study that gastric bypass surgery had a cure rate of 83% for obese type 2 diabetes, thus creating a new pathway for surgical treatment of type 2 diabetes. Patients with diabetes often face a lifetime of dietary control and lifelong medication, with numerous complications later in life. Diabetes means that while the patient’s internal organs are almost like being drenched in sugar, they and their families live with the disease. So in 2004, after introducing the idea of surgical treatment for type 2 diabetes back to China from the United States, I immediately started looking for information on the subject. Despite the relatively small amount of resource materials, he continued to explore and improve, and in 2008, he began to experiment with weight loss surgery to treat diabetes. In 2009, major domestic media began to report the news of weight loss surgery for diabetes, and patients continued to find the hospital for the surgery through news reports or friends’ introduction, and the news of surgical cure for diabetes gradually became known. The technology of bariatric surgery also began to mature and spread from various channels. Our team held several national, military and Guangdong Province classes on new technology of surgical treatment of diabetes between 2009 and 2012, and had extensive exchanges with domestic and foreign experts. The surgery is performed by making four small 1 cm holes in the patient’s stomach with special instruments, with special tubes going in, and through laparoscopic techniques, the surgeon completes the surgery inside the abdominal cavity. The mechanism of his treatment is to reduce food intake and absorption, thus reducing energy intake and metabolic load, and to change the secretion of hormones of the long insulin axis, thus improving glucose metabolism. Around 2011, after ten years of refinement and precipitation, weight reduction surgery for obese type 2 diabetes has been developed and matured, both in terms of improvement of surgical methods and case pathology studies, and considerable progress has been made. In addition, the assessment of surgical indications, contraindications to surgery, technical indicators, and perioperative management have been well developed. Our team has been working in the field of bariatric metabolic surgery for 10 years, and is one of the first teams in China to engage in bariatric surgery. We now not only have a very comprehensive preoperative examination and evaluation system, but also have established the first and largest health management department in China, and each patient is equipped with a professional health manager and nutritionist for long-term management and follow-up, which is also very optimistic in terms of clinical results. In 2014, I participated in the development of the Chinese Guidelines for the Surgical Treatment of Obesity and Type 2 Diabetes (2014), which refers to the standardized application of bariatric surgical modalities in the treatment of metabolic diseases such as type 2 diabetes and the promotion of their healthy and orderly development. The guidelines focus on the category of treating type 2 diabetes by means of bariatric surgery as the primary purpose, referring to the previous expert guidance and consensus in China, as well as the various editions of guidelines in the United States and other Western countries, absorbing and adopting the relevant literature in this field in China in recent years, and writing according to the current situation in China and the physical characteristics of the population. It is since then that major hospitals in China have started to boldly carry out weight loss surgery for obese type 2 diabetes. In 2017, our center alone has accumulated more than 1,000 bariatric metabolic surgeries, and the results of clinical observations are optimistic: the overall efficiency rate of gastric bypass surgery hands is 95%, the complete remission rate (clinical cure rate) is 85%, which is higher than the industry average, and many patients are able to maintain their blood glucose at normal levels for a long time after surgery and reduce the occurrence of diabetic complications. With the current rapid increase in obesity and diabetes in China, it is hoped that in the future the diabetic population in China will be more effectively controlled and prevented with the rapid development of surgical treatment.